Immunoglobulin E (IgE) specific for cockroach allergens (sIgE (cockroach))

Polyclonal human IgE specific for cockroach allergens refers to the heterogeneous population of Immunoglobulin E antibodies produced by B cells in response to proteins from cockroaches, such as Blattella germanica or Periplaneta americana (Gao et al., 2023). These antibodies play a central role in the pathogenesis of allergic diseases, particularly in urban environments where cockroach infestation is common (NIH, 2024). Upon exposure to cockroach allergens, these specific IgE molecules bind to high-affinity FcεRI receptors on mast cells and basophils, leading to the release of inflammatory mediators like histamine and leukotrienes. This process triggers symptoms of allergic rhinitis and is a major risk factor for the development and exacerbation of severe asthma. Therapeutic strategies targeting this molecule include monoclonal antibodies like Omalizumab, which sequesters free IgE to prevent its binding to receptors (FDA, 2023). Additionally, allergen-specific immunotherapy (AIT) aims to induce immune tolerance by gradually exposing the patient to these specific allergens (WHO/IUIS, 2024). Monitoring levels of cockroach-specific IgE is crucial for diagnosing sensitivity and assessing the risk of respiratory distress in allergic patients. Research into the polyclonal nature of these antibodies helps in identifying the most potent allergenic components for better diagnostic and therapeutic outcomes.

Other names

Cockroach-specific IgEAnti-cockroach IgEHuman IgE specific for Blattella germanicaHuman IgE specific for Periplaneta americanaCockroach allergen-specific IgE

Binding to the Fc region of free IgE, specifically the Cε3 domain, to prevent its interaction with high-affinity FcεRI and low-affinity FcεRII (CD23) receptors on effector cells, thereby reducing serum free IgE levels and downregulating receptor expression.